Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Noven Pharmaceuticals reports phase III data on low-dose paroxetine mesilate

Dec. 29, 2011

Prosidion claims novel GPR119 receptor agonists/DPP IV inhibitors

Dec. 29, 2011

New inhibitors of sclerostin prepared in Hong Kong

Dec. 29, 2011

Repros Therapeutics reports phase IIb data on Androxal

Dec. 28, 2011

FDA advisory committee sets Qnexa NDA review date

Dec. 28, 2011

Promising preclinical data disclosed on new antiobesity therapy

Dec. 28, 2011

Trial of new patch for osteoporosis meets endpoints

Dec. 27, 2011

Janssen Pharmaceutica discloses novel estrogen-related receptor-alpha ligands

Dec. 27, 2011

Galaczym obtains new orphan drug status

Dec. 23, 2011

Novel somatostatin sst5 receptor antagonists synthesized

Dec. 23, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...